ReviewPharmaceutics2026
PK-Informed Microphysiological Systems: From Dynamic Dosing to Quantitative In Vitro-In Vivo Translation.
Review in Pharmaceutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Conventional in vitro drug evaluation relies largely on static concentration-response assays that fail to reproduce the dynamic pharmacokinetic (PK) profiles observed in vivo, contributing to the gap between preclinical findings and clinical outcomes. Recent advances in microphysiological systems (MPSs), particularly microfluidic organ-on-chip platforms, enable programmable concentration-time profiles that more closely mimic physiological drug exposure. These PK-informed platforms allow systematic investigation of schedule dependency, time-dependent pharmacodynamics (PD), and exposure-driven efficacy under controlled flow conditions. Spatially resolved analytical approaches further reveal heterogeneous drug penetration and metabolic responses within tissues, emphasizing the importance of spatiotemporal PK-PD coupling. Integration of multi-organ and vascularized chip systems with physiologically based pharmacokinetic (PBPK) modeling increasingly supports quantitative in vitro-in vivo translation. This review outlines how PK-informed MPSs can generate dynamic in vitro exposure and response data that inform PBPK modeling, thereby supporting quantitative in vitro-in vivo translation of drug disposition and response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.